Compile Data Set for Download or QSAR

Found 43 hits Enz. Inhib. hit(s) with all data for entry = 8181   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM47165 (US8957103, C1 | US9364459, I) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCO)c2ccccc12 |t:13| Show InChI InChI=1S/C24H24N2O6/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)25-23(20)28)16-13-26(9-6-10-27)17-8-5-4-7-15(16)17/h4-5,7-8,11-13,27H,6,9-10H2,1-3H3,(H,25,28,29)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235821 (US9364459, H) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCO)c2ccccc12 |t:13| Show InChI InChI=1S/C23H22N2O6/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)24-22(19)27)15-12-25(8-9-26)16-7-5-4-6-14(15)16/h4-7,10-12,26H,8-9H2,1-3H3,(H,24,27,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM50399331 (CHEMBL2180882 | US9364459, C) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2cnccc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-14-6-10(7-15(27-2)18(14)28-3)16-17(20(25)23-19(16)24)12-8-22-13-9-21-5-4-11(12)13/h4-9,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	<10	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM50399333 (CHEMBL2177142 | US9364459, D) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ccncc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-14-6-10(7-15(27-2)18(14)28-3)16-17(20(25)23-19(16)24)12-9-22-13-4-5-21-8-11(12)13/h4-9,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	23	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM50399334 (CHEMBL2180878 | US9364459, B) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ncccc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-13-7-10(8-14(27-2)17(13)28-3)15-16(20(25)23-19(15)24)12-9-22-18-11(12)5-4-6-21-18/h4-9H,1-3H3,(H,21,22)(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	37	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM50399331 (CHEMBL2180882 | US9364459, C) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2cnccc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-14-6-10(7-15(27-2)18(14)28-3)16-17(20(25)23-19(16)24)12-8-22-13-9-21-5-4-11(12)13/h4-9,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	48	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM50399333 (CHEMBL2177142 | US9364459, D) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ccncc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-14-6-10(7-15(27-2)18(14)28-3)16-17(20(25)23-19(16)24)12-9-22-13-4-5-21-8-11(12)13/h4-9,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	50	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM47167 (CHEMBL201511 | US8957103, Z1 | US9364459, A) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12 |t:13| Show InChI InChI=1S/C21H18N2O5/c1-26-15-8-11(9-16(27-2)19(15)28-3)17-18(21(25)23-20(17)24)13-10-22-14-7-5-4-6-12(13)14/h4-10,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	90	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235820 (US9364459, G) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C24H25N3O5/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)26-23(20)28)16-13-27(10-6-9-25)17-8-5-4-7-15(16)17/h4-5,7-8,11-13H,6,9-10,25H2,1-3H3,(H,26,28,29)/p+1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	129	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM50399334 (CHEMBL2180878 | US9364459, B) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ncccc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-13-7-10(8-14(27-2)17(13)28-3)15-16(20(25)23-19(15)24)12-9-22-18-11(12)5-4-6-21-18/h4-9H,1-3H3,(H,21,22)(H,23,24,25)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	132	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235821 (US9364459, H) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCO)c2ccccc12 |t:13| Show InChI InChI=1S/C23H22N2O6/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)24-22(19)27)15-12-25(8-9-26)16-7-5-4-6-14(15)16/h4-7,10-12,26H,8-9H2,1-3H3,(H,24,27,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	153	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM47167 (CHEMBL201511 | US8957103, Z1 | US9364459, A) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12 |t:13| Show InChI InChI=1S/C21H18N2O5/c1-26-15-8-11(9-16(27-2)19(15)28-3)17-18(21(25)23-20(17)24)13-10-22-14-7-5-4-6-12(13)14/h4-10,22H,1-3H3,(H,23,24,25)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	166	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM50309549 (3-(5-Fluoro-1H-indol-3-yl)-4-(3,4,5-trimethoxyphen...) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ccc(F)cc12 |t:13| Show InChI InChI=1S/C21H17FN2O5/c1-27-15-6-10(7-16(28-2)19(15)29-3)17-18(21(26)24-20(17)25)13-9-23-14-5-4-11(22)8-12(13)14/h4-9,23H,1-3H3,(H,24,25,26)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	182	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235819 (US9364459, F) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C23H23N3O5/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)25-22(19)27)15-12-26(9-8-24)16-7-5-4-6-14(15)16/h4-7,10-12H,8-9,24H2,1-3H3,(H,25,27,28)/p+1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	195	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM50399332 (CHEMBL2180881 | US9364459, E) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2cccnc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-13-7-10(8-14(27-2)18(13)28-3)15-16(20(25)23-19(15)24)11-9-22-12-5-4-6-21-17(11)12/h4-9,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	215	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235819 (US9364459, F) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C23H23N3O5/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)25-22(19)27)15-12-26(9-8-24)16-7-5-4-6-14(15)16/h4-7,10-12H,8-9,24H2,1-3H3,(H,25,27,28)/p+1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	227	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM50399332 (CHEMBL2180881 | US9364459, E) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2cccnc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-13-7-10(8-14(27-2)18(13)28-3)15-16(20(25)23-19(15)24)11-9-22-12-5-4-6-21-17(11)12/h4-9,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	373	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235821 (US9364459, H) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCO)c2ccccc12 |t:13| Show InChI InChI=1S/C23H22N2O6/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)24-22(19)27)15-12-25(8-9-26)16-7-5-4-6-14(15)16/h4-7,10-12,26H,8-9H2,1-3H3,(H,24,27,28)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	554	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM47165 (US8957103, C1 | US9364459, I) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCO)c2ccccc12 |t:13| Show InChI InChI=1S/C24H24N2O6/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)25-23(20)28)16-13-26(9-6-10-27)17-8-5-4-7-15(16)17/h4-5,7-8,11-13,27H,6,9-10H2,1-3H3,(H,25,28,29)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	556	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235825 (US9364459, M) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN2CCOCC2)c2ccccc12 |t:13| Show InChI InChI=1S/C27H29N3O6/c1-33-21-14-17(15-22(34-2)25(21)35-3)23-24(27(32)28-26(23)31)19-16-30(20-7-5-4-6-18(19)20)9-8-29-10-12-36-13-11-29/h4-7,14-16H,8-13H2,1-3H3,(H,28,31,32)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	657	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM47165 (US8957103, C1 | US9364459, I) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCO)c2ccccc12 |t:13| Show InChI InChI=1S/C24H24N2O6/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)25-23(20)28)16-13-26(9-6-10-27)17-8-5-4-7-15(16)17/h4-5,7-8,11-13,27H,6,9-10H2,1-3H3,(H,25,28,29)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	920	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235820 (US9364459, G) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C24H25N3O5/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)26-23(20)28)16-13-27(10-6-9-25)17-8-5-4-7-15(16)17/h4-5,7-8,11-13H,6,9-10,25H2,1-3H3,(H,26,28,29)/p+1	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235823 (US9364459, K) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCN(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C26H29N3O5/c1-28(2)11-8-12-29-15-18(17-9-6-7-10-19(17)29)23-22(25(30)27-26(23)31)16-13-20(32-3)24(34-5)21(14-16)33-4/h6-7,9-10,13-15H,8,11-12H2,1-5H3,(H,27,30,31)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235824 (US9364459, L) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN2CCCCC2)c2ccccc12 |t:13| Show InChI InChI=1S/C28H31N3O5/c1-34-22-15-18(16-23(35-2)26(22)36-3)24-25(28(33)29-27(24)32)20-17-31(21-10-6-5-9-19(20)21)14-13-30-11-7-4-8-12-30/h5-6,9-10,15-17H,4,7-8,11-14H2,1-3H3,(H,29,32,33)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235822 (US9364459, J) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C25H27N3O5/c1-27(2)10-11-28-14-17(16-8-6-7-9-18(16)28)22-21(24(29)26-25(22)30)15-12-19(31-3)23(33-5)20(13-15)32-4/h6-9,12-14H,10-11H2,1-5H3,(H,26,29,30)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM47167 (CHEMBL201511 | US8957103, Z1 | US9364459, A) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12 |t:13| Show InChI InChI=1S/C21H18N2O5/c1-26-15-8-11(9-16(27-2)19(15)28-3)17-18(21(25)23-20(17)24)13-10-22-14-7-5-4-6-12(13)14/h4-10,22H,1-3H3,(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	1.10E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235824 (US9364459, L) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN2CCCCC2)c2ccccc12 |t:13| Show InChI InChI=1S/C28H31N3O5/c1-34-22-15-18(16-23(35-2)26(22)36-3)24-25(28(33)29-27(24)32)20-17-31(21-10-6-5-9-19(20)21)14-13-30-11-7-4-8-12-30/h5-6,9-10,15-17H,4,7-8,11-14H2,1-3H3,(H,29,32,33)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.21E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235824 (US9364459, L) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN2CCCCC2)c2ccccc12 |t:13| Show InChI InChI=1S/C28H31N3O5/c1-34-22-15-18(16-23(35-2)26(22)36-3)24-25(28(33)29-27(24)32)20-17-31(21-10-6-5-9-19(20)21)14-13-30-11-7-4-8-12-30/h5-6,9-10,15-17H,4,7-8,11-14H2,1-3H3,(H,29,32,33)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.24E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235822 (US9364459, J) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C25H27N3O5/c1-27(2)10-11-28-14-17(16-8-6-7-9-18(16)28)22-21(24(29)26-25(22)30)15-12-19(31-3)23(33-5)20(13-15)32-4/h6-9,12-14H,10-11H2,1-5H3,(H,26,29,30)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.30E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235820 (US9364459, G) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C24H25N3O5/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)26-23(20)28)16-13-27(10-6-9-25)17-8-5-4-7-15(16)17/h4-5,7-8,11-13H,6,9-10,25H2,1-3H3,(H,26,28,29)/p+1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM50399332 (CHEMBL2180881 | US9364459, E) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2cccnc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-13-7-10(8-14(27-2)18(13)28-3)15-16(20(25)23-19(15)24)11-9-22-12-5-4-6-21-17(11)12/h4-9,22H,1-3H3,(H,23,24,25)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	1.52E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235823 (US9364459, K) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCN(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C26H29N3O5/c1-28(2)11-8-12-29-15-18(17-9-6-7-10-19(17)29)23-22(25(30)27-26(23)31)16-13-20(32-3)24(34-5)21(14-16)33-4/h6-7,9-10,13-15H,8,11-12H2,1-5H3,(H,27,30,31)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.53E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235819 (US9364459, F) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CC[NH3+])c2ccccc12 |t:13| Show InChI InChI=1S/C23H23N3O5/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)25-22(19)27)15-12-26(9-8-24)16-7-5-4-6-14(15)16/h4-7,10-12H,8-9,24H2,1-3H3,(H,25,27,28)/p+1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.89E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM50399331 (CHEMBL2180882 | US9364459, C) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2cnccc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-14-6-10(7-15(27-2)18(14)28-3)16-17(20(25)23-19(16)24)12-8-22-13-9-21-5-4-11(12)13/h4-9,22H,1-3H3,(H,23,24,25)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	1.90E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235826 (US9364459, N) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH+]2CC[NH+](C)CC2)c2ccccc12 |t:13,(1.93,-1.66,;3.42,-1.27,;3.82,.22,;2.73,1.31,;3.13,2.8,;4.61,3.2,;5.7,2.11,;7.19,2.51,;7.59,3.99,;5.3,.62,;6.39,-.47,;7.88,-.07,;2.36,4.13,;.82,4.13,;.34,5.6,;-.99,6.37,;1.59,6.5,;2.83,5.6,;4.17,6.37,;.05,2.8,;.52,1.33,;-.72,.43,;-.72,-1.11,;-2.06,-1.88,;-2.06,-3.42,;-3.39,-4.19,;-4.73,-3.42,;-6.06,-4.19,;-6.06,-5.73,;-7.88,-6.5,;-4.73,-6.5,;-3.39,-5.73,;-1.97,1.33,;-3.48,1.01,;-4.51,2.16,;-4.03,3.62,;-2.52,3.94,;-1.49,2.8,)| Show InChI InChI=1S/C29H34N4O5/c1-31-12-14-32(15-13-31)10-7-11-33-18-21(20-8-5-6-9-22(20)33)26-25(28(34)30-29(26)35)19-16-23(36-2)27(38-4)24(17-19)37-3/h5-6,8-9,16-18H,7,10-15H2,1-4H3,(H,30,34,35)/p+2	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.83E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235826 (US9364459, N) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH+]2CC[NH+](C)CC2)c2ccccc12 |t:13,(1.93,-1.66,;3.42,-1.27,;3.82,.22,;2.73,1.31,;3.13,2.8,;4.61,3.2,;5.7,2.11,;7.19,2.51,;7.59,3.99,;5.3,.62,;6.39,-.47,;7.88,-.07,;2.36,4.13,;.82,4.13,;.34,5.6,;-.99,6.37,;1.59,6.5,;2.83,5.6,;4.17,6.37,;.05,2.8,;.52,1.33,;-.72,.43,;-.72,-1.11,;-2.06,-1.88,;-2.06,-3.42,;-3.39,-4.19,;-4.73,-3.42,;-6.06,-4.19,;-6.06,-5.73,;-7.88,-6.5,;-4.73,-6.5,;-3.39,-5.73,;-1.97,1.33,;-3.48,1.01,;-4.51,2.16,;-4.03,3.62,;-2.52,3.94,;-1.49,2.8,)| Show InChI InChI=1S/C29H34N4O5/c1-31-12-14-32(15-13-31)10-7-11-33-18-21(20-8-5-6-9-22(20)33)26-25(28(34)30-29(26)35)19-16-23(36-2)27(38-4)24(17-19)37-3/h5-6,8-9,16-18H,7,10-15H2,1-4H3,(H,30,34,35)/p+2	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.24E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235822 (US9364459, J) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C25H27N3O5/c1-27(2)10-11-28-14-17(16-8-6-7-9-18(16)28)22-21(24(29)26-25(22)30)15-12-19(31-3)23(33-5)20(13-15)32-4/h6-9,12-14H,10-11H2,1-5H3,(H,26,29,30)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.58E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM50399333 (CHEMBL2177142 | US9364459, D) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ccncc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-14-6-10(7-15(27-2)18(14)28-3)16-17(20(25)23-19(16)24)12-9-22-13-4-5-21-8-11(12)13/h4-9,22H,1-3H3,(H,23,24,25)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	6.27E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235825 (US9364459, M) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN2CCOCC2)c2ccccc12 |t:13| Show InChI InChI=1S/C27H29N3O6/c1-33-21-14-17(15-22(34-2)25(21)35-3)23-24(27(32)28-26(23)31)19-16-30(20-7-5-4-6-18(19)20)9-8-29-10-12-36-13-11-29/h4-7,14-16H,8-13H2,1-3H3,(H,28,31,32)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9.20E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM50399334 (CHEMBL2180878 | US9364459, B) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1c[nH]c2ncccc12 |t:13| Show InChI InChI=1S/C20H17N3O5/c1-26-13-7-10(8-14(27-2)17(13)28-3)15-16(20(25)23-19(15)24)12-9-22-18-11(12)5-4-6-21-18/h4-9H,1-3H3,(H,21,22)(H,23,24,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	>1.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235826 (US9364459, N) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCC[NH+]2CC[NH+](C)CC2)c2ccccc12 |t:13,(1.93,-1.66,;3.42,-1.27,;3.82,.22,;2.73,1.31,;3.13,2.8,;4.61,3.2,;5.7,2.11,;7.19,2.51,;7.59,3.99,;5.3,.62,;6.39,-.47,;7.88,-.07,;2.36,4.13,;.82,4.13,;.34,5.6,;-.99,6.37,;1.59,6.5,;2.83,5.6,;4.17,6.37,;.05,2.8,;.52,1.33,;-.72,.43,;-.72,-1.11,;-2.06,-1.88,;-2.06,-3.42,;-3.39,-4.19,;-4.73,-3.42,;-6.06,-4.19,;-6.06,-5.73,;-7.88,-6.5,;-4.73,-6.5,;-3.39,-5.73,;-1.97,1.33,;-3.48,1.01,;-4.51,2.16,;-4.03,3.62,;-2.52,3.94,;-1.49,2.8,)| Show InChI InChI=1S/C29H34N4O5/c1-31-12-14-32(15-13-31)10-7-11-33-18-21(20-8-5-6-9-22(20)33)26-25(28(34)30-29(26)35)19-16-23(36-2)27(38-4)24(17-19)37-3/h5-6,8-9,16-18H,7,10-15H2,1-4H3,(H,30,34,35)/p+2	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235825 (US9364459, M) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCN2CCOCC2)c2ccccc12 |t:13| Show InChI InChI=1S/C27H29N3O6/c1-33-21-14-17(15-22(34-2)25(21)35-3)23-24(27(32)28-26(23)31)19-16-30(20-7-5-4-6-18(19)20)9-8-29-10-12-36-13-11-29/h4-7,14-16H,8-13H2,1-3H3,(H,28,31,32)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235823 (US9364459, K) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCN(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C26H29N3O5/c1-28(2)11-8-12-29-15-18(17-9-6-7-10-19(17)29)23-22(25(30)27-26(23)31)16-13-20(32-3)24(34-5)21(14-16)33-4/h6-7,9-10,13-15H,8,11-12H2,1-5H3,(H,27,30,31)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair